Pdt Partners, LLC Arcus Biosciences, Inc. Transaction History

Pdt Partners, LLC

$1.58 Billion
Q2 2025

A detailed history of Pdt Partners, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 389,287 shares of RCUS stock, worth $3.76 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

389,287

Previous 90,298 331.11%

Holding current value

$3.76 Million

Previous $708,000 347.46%

% of portfolio

0.2%

Previous 0.06%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$6.87 - $10.03 $2.05 Million - $3 Million	298,989 Added 331.11%	389,287 $3.17 Million
Q1 2025 May 15, 2025	SELL	$7.85 - $15.24 $278,313 - $540,318	-35,454 Reduced 28.19%	90,298 $708,000
Q4 2024 Feb 14, 2025	BUY	$14.28 - $18.44 $544,296 - $702,859	38,116 Added 43.49%	125,752 $1.87 Million
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $196,738 - $258,821	14,371 Added 19.62%	87,636 $1.34 Million
Q2 2024 Aug 15, 2024	SELL	$14.59 - $18.48 $348,511 - $441,431	-23,887 Reduced 24.59%	73,265 $1.12 Million
Q1 2024 May 15, 2024	BUY	$14.83 - $20.18 $1.22 Million - $1.66 Million	82,178 Added 548.8%	97,152 $1.83 Million
Q4 2023 Feb 14, 2024	BUY	$13.43 - $19.63 $201,100 - $293,939	14,974 New	14,974 $286,000
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $212,236 - $307,848	13,298 Added 34.43%	51,925 $947,000
Q4 2022 Feb 14, 2023	SELL	$19.7 - $35.71 $392,049 - $710,664	-19,901 Reduced 34.0%	38,627 $798,000
Q3 2022 Nov 14, 2022	BUY	$23.23 - $30.07 $718,039 - $929,463	30,910 Added 111.92%	58,528 $1.53 Million
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $475,858 - $1.04 Million	27,618 New	27,618 $700,000
Q1 2022 May 16, 2022	SELL	$28.92 - $41.83 $146,074 - $211,283	-5,051 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$31.38 - $48.47 $158,500 - $244,821	5,051 New	5,051 $204,000
Q4 2020 Feb 16, 2021	SELL	$17.0 - $32.36 $412,199 - $784,632	-24,247 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $415,593 - $617,571	24,247 New	24,247 $416,000
Q2 2020 Aug 14, 2020	SELL	$13.97 - $36.56 $237,951 - $622,726	-17,033 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$8.78 - $19.28 $22,204 - $48,759	-2,529 Reduced 12.93%	17,033 $236,000
Q4 2019 Feb 14, 2020	SELL	$7.33 - $10.79 $25,933 - $38,175	-3,538 Reduced 15.32%	19,562 $198,000
Q3 2019 Nov 14, 2019	BUY	$6.44 - $10.18 $41,216 - $65,152	6,400 Added 38.32%	23,100 $210,000
Q2 2019 Aug 14, 2019	BUY	$7.29 - $13.38 $121,743 - $223,446	16,700 New	16,700 $133,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

65.5M

Call Options Held

3.1M

Put Options Held

148K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $698M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account